LABCORP HOLDINGS INC. (LH) stock intrinsic value fair value estimate & owner earnings analysis

Labcorp is one of the two large national clinical laboratory testing companies in the United States, running blood, pathology and specialty diagnostic tests for patients and health systems (the Diagnostics business), alongside a smaller lab-services business that supports drug developers (Biopharma Laboratory Services). In mid-2023 the company separated its clinical-trials contract research business, Fortrea, into an independent public company. That separation is the key event shaping this analysis: it materially changed the size and mix of the business, so our estimate of normal, sustainable owner earnings is built only from the years describing the company as it exists today (2022 through 2025), not the larger combined entity that existed before the spin-off. Owner earnings for those four years, per diluted share, ranged from about $11 to about $20, with the swings driven mainly by year-to-year working-capital timing and by the fade-out of elevated COVID-19 testing volumes that had inflated 2021 results; the middle (median) of that range, about $15.60 per share, is our estimate of what the current business earns for its owners in a typical year. A meaningful accounting judgment underlies this figure: Labcorp carries large annual depreciation and amortization charges, including goodwill and intangible write-offs tied to decades of laboratory acquisitions, which we add back in full because they are non-cash. We separately estimate the portion of capital spending needed just to sustain the existing business (as opposed to fund growth) and only deduct that maintenance portion, which is meaningfully less than total depreciation and amortization - a normal feature of an asset-light service business built partly through acquisition. Looking ahead, we see three broad paths for the business. Our base case assumes Labcorp keeps growing owner earnings at a mid-single-digit annual pace over the next decade, powered by an aging population's growing need for testing, continued growth in higher-value specialty and esoteric testing, and Labcorp's long-running strategy of buying smaller hospital and regional lab businesses to add volume. This growth is partly offset by scheduled cuts to Medicare's laboratory fee schedule (currently frozen for 2026 but set by law to resume, capped, from 2027 through 2029) and by continued pricing pressure from commercial insurers who often follow Medicare's lead. Beyond the ten-year forecast, we assume the business settles into a modest, roughly flat-to-slightly-growing level, reflecting a durable, recurring need for diagnostic testing that offsets an ongoing, structural drag from government reimbursement resets - a balance that, once discounted, we estimate at about $362 per share. Our bear case - roughly a one-in-ten downside outcome - assumes the 2027 Medicare cuts land harder than the law's caps currently suggest, commercial payers follow with further price cuts, competition from the other national lab and from hospitals building out their own testing erodes volume, and Labcorp responds by pausing its acquisition program to protect its balance sheet, which carries roughly $5.6 billion of net debt against a business earning $1.3-1.6 billion a year - manageable, but a real constraint in a downturn. Under that path we estimate the shares are worth around $145. Our bull case - roughly a one-in-ten upside outcome - assumes the specialty-testing mix shift and the acquisition strategy both perform better than normal, the Biopharma Laboratory Services business benefits from a pickup in drug-development activity, and reimbursement risk proves manageable within its statutory caps; that path is worth around $523 per share. In both the base and bull cases, more than roughly three-fifths of the total value comes from what the business is projected to earn beyond the ten-year mark, which is standard for a durable, recurring-demand healthcare service business, but it does mean the valuation leans heavily on the view that diagnostic testing demand keeps growing gently for a long time even as reimbursement rates are periodically reset downward - we think that is the more likely outcome, but it is worth understanding as the biggest single assumption behind the number. Weighing the uncertainty in the downside case, the margin-of-safety price is around $210, a discount to our mid-case estimate that reflects the real, dated regulatory risk (the 2027-2029 Medicare fee cuts) and moderate balance-sheet leverage, alongside the recurring, non-discretionary nature of the underlying testing volumes. One item we could not fully reconcile from the filings: the separation-related cash flows in the transition year (2023) blend a partial year of the divested clinical-trials business with the continuing diagnostics business in a few balance-sheet-linked cash flow lines; we believe the effect on our estimate is modest, but flag it for transparency.